Multiple Sclerosis, Relapsing-Remitting - 31 Studies Found
| Withdrawn |
: QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea : Multiple Sclerosis, Relapsing-Remitting : 2010-02-18 : Drug: Interferon beta 1-b (Betaferon/Betaseron, BAY86-5046) Patients receiving Betaferon according to ro |
| Active, not recruiting |
: Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) : Multiple Sclerosis, Relapsing-Remitting : 2015-09-17 : Drug: dimethyl fumarate administered orally Other Na |
| Completed |
: Evaluation of a Modified Paleolithic Dietary Intervention in the Treatment of Relapsing-Remitting Multiple Sclerosis : Multiple Sclerosis, Relapsing-remitting : 2016-01-22 : Other: Modified Paleo diet Nine cups of vegetables and some fruits, meat protein including organ meat, a |
| Completed |
: A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) : Multiple Sclerosis, Relapsing-Remitting : 2005-09-13 :
|
| Recruiting |
: Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS) : Multiple Sclerosis, Relapsing-Remitting : 2017-03-16 : Drug: Ocrelizumab Ocrelizumab will be administered via IV infusion as specified throughout the treatment |
| Recruiting |
: Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple Sclerosis : Multiple Sclerosis, Relapsing-Remitting : 2015-05-27 : Drug: Dimethyl fumarate Dimethyl fumarate (Tecfidera®) treatment is initiated by daily administrati |
| Recruiting |
: A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) : Multiple Sclerosis, Relapsing-Remitting : 2015-12-18 : Drug: Ocrelizumab Participants will receive ocrelizumab as an initial dose of two 300-mg IV infusions (6 |
| Terminated |
: A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS) : Multiple Sclerosis, Relapsing-Remitting : 2013-03-07 :
|
| Completed |
: Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis : Multiple Sclerosis, Relapsing-Remitting : 2005-10-10 :
|
| Not yet recruiting |
: Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis : Multiple Sclerosis, Relapsing-Remitting : 2016-04-03 :
|